{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:55:13Z","timestamp":1795038913855,"version":"4.10.2"},"reference-count":50,"publisher":"BMJ","issue":"10","funder":[{"name":"NIH","award":["P30 CA016086; UL1TR002489"],"award-info":[{"award-number":["P30 CA016086; UL1TR002489"]}]},{"name":"NIH","award":["P30 DK034987"],"award-info":[{"award-number":["P30 DK034987"]}]},{"name":"NIH","award":["UM1TR004406"],"award-info":[{"award-number":["UM1TR004406"]}]},{"name":"GlakoSmithKline","award":["GSK ISS 209033"],"award-info":[{"award-number":["GSK ISS 209033"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2023,6,28]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentre, randomised, double-blind, placebo-controlled, trial. In the first part, patients aged 16\u201375 with EoE and dysphagia symptoms (per EoE Symptom Activity Index (EEsAI)) were randomised 1:1 to 3 months of mepolizumab 300\u2009mg monthly or placebo. Primary outcome was change in EEsAI from baseline to month 3 (M3). Secondary outcomes included histological, endoscopic and safety metrics. In part 2, patients initially randomised to mepolizumab continued 300\u2009mg monthly for 3 additional months (mepo\/mepo), placebo patients started mepolizumab 100\u2009mg monthly (pbo\/mepo), and outcomes were reassessed at month 6 (M6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 66 patients randomised, 64 completed M3, and 56 completed M6. At M3, EEsAI decreased 15.4\u00b118.1 with mepolizumab and 8.3\u00b118.0 with placebo (p=0.14). Peak eosinophil counts decreased more with mepolizumab (113\u00b177\u2009to 36\u00b143) than placebo (146\u00b194\u2009to 160\u00b1133) (p&lt;0.001). With mepolizumab, 42% and 34% achieved histological responses of &lt;15\u2009and \u22646 eos\/hpf compared with 3% and 3% with placebo (p&lt;0.001\u2009and 0.02). The change in EoE Endoscopic Reference Score at M3 was also larger with mepolizumab. At M6, EEsAI decreased 18.3\u00b118.1 points for mepo\/mepo and 18.6\u00b119.2 for pbo\/mepo (p=0.85). The most common adverse events were injection-site reactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Mepolizumab did not achieve the primary endpoint of improving dysphagia symptoms compared with placebo. While eosinophil counts and endoscopic severity improved with mepolizumab at 3 months, longer treatment did not yield additional improvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03656380\">NCT03656380<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2023-330337","type":"journal-article","created":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T13:20:14Z","timestamp":1688908814000},"page":"1828-1837","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":109,"title":["Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial"],"prefix":"10.1136","volume":"72","clinical-trial-number":[{"clinical-trial-number":"nct03656380","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1167-1101","authenticated-orcid":false,"given":"Evan S","family":"Dellon","sequence":"first","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L","family":"Mitlyng","sequence":"additional","affiliation":[{"name":"MNGI Digestive Health, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Iuga","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Bookhout","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M","family":"Cortright","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacie B","family":"Walker","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S","family":"Gee","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"McGee","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenderia A","family":"Cameron","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Galanko","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Woosley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Eluri","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Moist","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-9377","authenticated-orcid":false,"given":"Ikuo","family":"Hirano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Northwestern University School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,9]]},"reference":[{"key":"2025090713343248000_72.10.1828.1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.065"},{"key":"2025090713343248000_72.10.1828.3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/apt.13129","article-title":"The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice","volume":"41","author":"Dellon","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090713343248000_72.10.1828.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2013.10.027"},{"key":"2025090713343248000_72.10.1828.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.08.015"},{"key":"2025090713343248000_72.10.1828.6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1053\/j.gastro.2020.02.039","article-title":"Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters","volume":"158","author":"Rank","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s10620-017-4642-7","article-title":"Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression","volume":"62","author":"Cotton","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2025090713343248000_72.10.1828.9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2014.07.034","article-title":"Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients","volume":"13","author":"Wolf","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.10","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.27","article-title":"Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis","volume":"8","author":"Eluri","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2025090713343248000_72.10.1828.11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.cgh.2021.06.020","article-title":"Long-term treatment of eosinophilic esophagitis with budesonide oral suspension","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.16","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090713343248000_72.10.1828.17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2022.12.014","article-title":"Clinical guidance for the use of dupilumab in eosinophilic esophagitis: a yardstick","volume":"130","author":"Aceves","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025090713343248000_72.10.1828.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.002"},{"key":"2025090713343248000_72.10.1828.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.5.2464"},{"key":"2025090713343248000_72.10.1828.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303631"},{"key":"2025090713343248000_72.10.1828.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812"},{"key":"2025090713343248000_72.10.1828.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025090713343248000_72.10.1828.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"2025090713343248000_72.10.1828.24","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178558"},{"key":"2025090713343248000_72.10.1828.25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.07.044"},{"key":"2025090713343248000_72.10.1828.26","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.cgh.2019.01.030","article-title":"A conceptual approach to understanding treatment response in eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.028"},{"key":"2025090713343248000_72.10.1828.28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025090713343248000_72.10.1828.29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13370"},{"key":"2025090713343248000_72.10.1828.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.11.004"},{"key":"2025090713343248000_72.10.1828.31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a Monoclonal antibody against Il13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cgh.2017.09.046","article-title":"Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study","volume":"16","author":"Reed","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1005-z"},{"key":"2025090713343248000_72.10.1828.34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2016.12.017","article-title":"Determination of esophageal eosinophil counts and other histologic features of eosinophilic esophagitis by pathology trainees is highly accurate","volume":"62","author":"Rusin","year":"2017","journal-title":"Hum Pathol"},{"key":"2025090713343248000_72.10.1828.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2006.04.037"},{"key":"2025090713343248000_72.10.1828.36","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301817"},{"key":"2025090713343248000_72.10.1828.37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cgh.2015.08.040","article-title":"Accuracy of the eosinophilic esophagitis endoscopic reference score in diagnosis and determining response to treatment","volume":"14","author":"Dellon","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.38","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.048"},{"key":"2025090713343248000_72.10.1828.39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.007"},{"key":"2025090713343248000_72.10.1828.41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2022.03.025","article-title":"A clinical severity index for eosinophilic esophagitis: development, consensus, and future directions","volume":"163","author":"Dellon","year":"2022","journal-title":"Gastroenterology"},{"key":"2025090713343248000_72.10.1828.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.044"},{"key":"2025090713343248000_72.10.1828.43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of Reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years","volume":"66","author":"Markowitz","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025090713343248000_72.10.1828.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.03.018"},{"key":"2025090713343248000_72.10.1828.45","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14061"},{"key":"2025090713343248000_72.10.1828.46","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.14309\/ajg.0000000000000957","article-title":"Dilation modifies association between symptoms and esophageal eosinophilia in adult patients with eosinophilic esophagitis","volume":"115","author":"Safroneeva","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025090713343248000_72.10.1828.47","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cgh.2021.05.049","article-title":"Long-lasting dissociation of esophageal eosinophilia and symptoms following dilation in adults with eosinophilic esophagitis","volume":"20","author":"Safroneeva","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090713343248000_72.10.1828.48","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","article-title":"Results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE","volume":"117","author":"Dellon","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025090713343248000_72.10.1828.49","doi-asserted-by":"crossref","unstructured":"Rothenberg ME , Dellon ES , Collins MH , et al . Efficacy and safety of Benralizumab in adults and adolescents with eosinophilic Esophagitis: results from the 24-week double-blind period of the phase 3 MESSINA trial. Gastroenterology 2023;64 (Suppl).","DOI":"10.1016\/S0016-5085(23)01239-8"},{"key":"2025090713343248000_72.10.1828.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.042"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2023-330337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:34:41Z","timestamp":1757277281000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2023-330337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/gutjnl-2023-330337"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2023-330337","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,9]]}}}